Bli medlem
Bli medlem

Du är här


Herantis Pharma Oyj: Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders

Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders

Herantis Pharma Plc
Company release 11 April 2016 at 5:00 PM

The Annual General Meeting of Shareholders of Herantis Pharma Plc was held in
Helsinki on Monday, 11 April 2016.

Matters pertaining to the Annual General Meeting

The Annual General Meeting adopted the consolidated financial statements and
the parent company's financial statements for the financial year 2015 and
discharged the members of the Board of Directors and the CEO from liability.
The Annual General Meeting of Shareholders decided that, as proposed by the
Board of Directors, no dividend be paid for the financial year 1 January - 31
December 2015 and that the loss for the financial year shall be entered in
the compilation of loss.

The Annual General Meeting resolved that the remuneration payable to the
members of the Board of Directors shall be EUR 1,000 per month except for the
Chairman of the Board who shall be paid EUR 2,000 monthly. It was further
resolved that the board members shall also be eligible to subscribe to stock
options of option program 2014 I, according to the rules of which the board
members can be given stock options for each full 12 month period as a Board

The Annual General Meeting decided that the Auditor will be paid reasonable
remuneration in accordance with the invoice approved by the Company.

The firm of authorised public accountants PricewaterhouseCoopers Oy was
appointed as Herantis Pharma Plc's Auditor for the term ending at the end of
the next Annual General Meeting of Shareholders, with APA Martin Grandell as
the responsible auditor.


Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web

Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246

About Herantis Pharma Plc

Herantis Pharma Plc is a drug development company focused on early clinical
development of innovative drugs in unmet clinical needs. Our special emphasis
is in regenerative medicine where the company has two first-in-class assets
based on globally leading science in their fields: CDNF for neurodegenerative
diseases, primarily Parkinson's and ALS; and Lymfactin® for breast cancer
associated lymphedema, with potential also in primary lymphedema. The shares
of Herantis are listed on the First North Finland marketplace run by Nasdaq
Helsinki stock exchange.


Nasdaq Helsinki
Main media


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.